NASDAQ:ARNA - Arena Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$43.23 -2.43 (-5.32 %)
(As of 03/24/2019 04:00 PM ET)
Previous Close$43.23
Today's Range$43.09 - $45.5450
52-Week Range$31.97 - $51.63
Volume540,084 shs
Average Volume497,553 shs
Market Capitalization$2.14 billion
P/E Ratio-14.65
Dividend YieldN/A
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. Its proprietary investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod that is in Phase II trials for treating immune and inflammatory conditions with primary focus on ulcerative colitis and hepatic conditions, as well as for primary biliary cholangitis and pyoderma gangrenosum; and APD371, which is in Phase II trial for the treatment of pain associated with Crohn's disease. The company has collaboration agreements with Everest Medicines Limited; Axovant Sciences GmbH; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ARNA



Sales & Book Value

Annual Sales$17.97 million
Book Value$12.27 per share


Net Income$-29,400,000.00
Net Margins-163.60%


Market Cap$2.14 billion
Next Earnings Date5/14/2019 (Estimated)

Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Shares of Arena Pharmaceuticals reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its quarterly earnings data on Tuesday, February, 26th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.76) by $2.11. The biopharmaceutical company earned $8.65 million during the quarter, compared to the consensus estimate of $3.33 million. Arena Pharmaceuticals had a negative net margin of 163.60% and a negative return on equity of 24.36%. The business's quarterly revenue was down 43.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.35) EPS. View Arena Pharmaceuticals' Earnings History.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Arena Pharmaceuticals.

What price target have analysts set for ARNA?

5 brokers have issued 1-year target prices for Arena Pharmaceuticals' stock. Their predictions range from $55.00 to $70.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $61.60 in the next year. This suggests a possible upside of 42.5% from the stock's current price. View Analyst Price Targets for Arena Pharmaceuticals.

What is the consensus analysts' recommendation for Arena Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arena Pharmaceuticals.

What are Wall Street analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and $62 price target. Arena today (2/26) reported 4Q18 earnings, with all programs remaining on track, including pivotal Ph3 initiations in 2019 for etrasimod in ulcerative colitis (UC) and Crohn’s. We are adjusting our estimates to reflect increasing investment in R&D as the pipeline advances. Over the next 12-18 months, we see opportunities like olorinab and etrasimod expansion as underappreciated at current levels. With many Ph2 and 3 trials reading out in 2020, we expect investors to take note, and we see little downside risk in the interim." (2/26/2019)
  • 2. According to Zacks Investment Research, "Arena Pharmaceuticals reported is focused on developing its three pipeline candidates – ralinepag, etrasimod and olorinab. The company has signed an agreement with United Therapeutics to divest Ralinepag for $1.2 billion. The company’s collaboration agreements provide milestone payments and steady revenue stream from royalties on Belviq sales. Meanwhile, the company’s decision to sell its manufacturing operations to focus on pipeline is prudent, in our view. However, all of Arena’s pipeline candidates are in mid-stage development, which is a concern as any setback will have negative impact on Arena’s prospects. Dependence on Belviq royalties is also concerning as the drug’s performance has been lackluster lately in a competitive market. Shares of the company have outperformed the industry in the past six months." (1/15/2019)

Has Arena Pharmaceuticals been receiving favorable news coverage?

News headlines about ARNA stock have trended neutral this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Arena Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the stock's share price in the next several days.

Who are some of Arena Pharmaceuticals' key competitors?

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Micron Technology (MU), Inovio Pharmaceuticals (INO), Canopy Growth (CGC), Opko Health (OPK), Advanced Micro Devices (AMD), AT&T (T), GW Pharmaceuticals PLC- (GWPH), Zynerba Pharmaceuticals (ZYNE), Cara Therapeutics (CARA) and Amarin (AMRN).

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the folowing people:
  • Mr. Amit D. Munshi, Pres, CEO & Director (Age 51)
  • Mr. Kevin R. Lind, Exec. VP & CFO (Age 43)
  • Mr. Steven W. Spector, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Vincent E. Aurentz, Chief Bus. Officer & Exec. VP (Age 51)
  • Dr. Preston S. Klassen, Chief Medical Officer and Exec. VP of R&D (Age 50)

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.67%), Partner Fund Management L.P. (6.10%), FMR LLC (4.23%), Perceptive Advisors LLC (2.89%), Northern Trust Corp (1.21%) and Geode Capital Management LLC (1.14%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Preston Klassen, Steven W Spector and Tina Susan Nova. View Institutional Ownership Trends for Arena Pharmaceuticals.

Which institutional investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Tekla Capital Management LLC, Eversept Partners LP, Barclays PLC, Squarepoint Ops LLC, First Trust Advisors LP and Chartwell Investment Partners LLC. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Preston Klassen, Steven W Spector and Tina Susan Nova. View Insider Buying and Selling for Arena Pharmaceuticals.

Which institutional investors are buying Arena Pharmaceuticals stock?

ARNA stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Partner Fund Management L.P., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, ETF Managers Group LLC, Candriam Luxembourg S.C.A., Perceptive Advisors LLC and Geode Capital Management LLC. View Insider Buying and Selling for Arena Pharmaceuticals.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $43.23.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $2.14 billion and generates $17.97 million in revenue each year. The biopharmaceutical company earns $-29,400,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]

MarketBeat Community Rating for Arena Pharmaceuticals (NASDAQ ARNA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  357 (Vote Underperform)
Total Votes:  675
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by Staff

Featured Article: What is the LIBOR?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel